For instance, previous studies have indicated that SPAG6 is significantly overexpressed in ovarian cancer (Coan et al., 2019), breast cancer (Siliņa et al., 2011), kidney renal papillary cell carcinoma (Li et al., 2024) and osteosarcoma. Here, SPAG6 is linked to osteosarcoma.